590
Views
31
CrossRef citations to date
0
Altmetric
Review Article

Persistent infectious diseases say – IDO. Role of indoleamine-2,3-dioxygenase in disease pathogenesis and implications for therapy

&
Pages 360-368 | Received 05 Jul 2012, Accepted 17 Oct 2012, Published online: 23 Nov 2012
 

Abstract

Indoleamine-2,3-dioxygenase (IDO) is an enzyme that catabolises tryptophan – an essential amino acid critical for T cell proliferation. Initially recognized as a first line of host defense against infectious pathogens, IDO has been subsequently identified as an important immune-regulator inhibiting T-cell responses and promoting immune tolerance. Research over the past few years has demonstrated a crucial role for IDO in the pathogenesis of persistent infections that place an enormous burden on public health. In this review, we summarize current knowledge about IDO’s role in causing pathogen persistence and progression to clinical disease. We conclude with a perspective on the potential benefits and risks of therapeutic IDO manipulation.

Search strategy and selection criteria

Data for this review were identified through searches of PubMed. Search terms “IDO”, “tryptophan”, “dendritic cells”, “HIV”, “HCV”, “leishmaniasis”, “tuberculosis”, “malaria”, “listeriosis”, “toxoplasmosis”, “candidasis”, “immunotherapy”, “tolerance”, and “cancer”. Articles resulting from these searches and relevant references cited in those articles were reviewed. Articles published in English were included. References were not limited by year of publication.

Acknowledgements

We thank F. Stoll-Keller and E. Soulier (Inserm U748, Strasbourg) for helpful discussion.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.